Cure My Disease

Don't miss your cure!

 Log in / Sign up

Neurodegenerative drug study ends early after only 17 participants

NCT ID NCT06111014

Disease control Sponsor: Alector Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

17 people

The number who actually took part.

Started

Dec 2023

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker). * Has successfully completed participation in their parent latozinemab study. * Female participants must be nonpregnant and nonlactating. * Male participants must agree to acceptable contraception use. Exclusion Criteria: * Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. * Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurodegenerative diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis frontotemporal dementia neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neurodegenerative diseases

Contacts and locations

Locations

  • Azienda Ospedaliero Universitaria Di Modena Policlinico

    Modena, 41126, Italy

  • Centro Hospitalar E Universitario de Coimbra EPE

    Coimbra, 3000-075, Portugal

  • Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria

    Lisbon, 1649-028, Portugal

  • Dignity Health - Arizona

    Phoenix, Arizona, 85013, United States

  • Erasmus MC-Dr. Molewaterplein 40

    Rotterdam, 3015 GD, Netherlands

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico -Via Fracesco Sforza 35

    Milan, 20122, Italy

  • Groupe Hospitalier Pitié Salpétrière

    Paris, 75013, France

  • IRCCS - Centro S. Giovanni di Dio Fatebenefratelli

    Brescia, 25125, Italy

  • Irving Institute for Clinical and Translational Research

    New York, New York, 10032, United States

  • Karolinska Universitetssjukhuset Huddinge

    Huddinge, SE-14186, Sweden

  • Mayo Comprehensive Cancer Center - PPDS

    Rochester, Minnesota, 55905, United States

  • Parkwood Institute

    London, Ontario, N6C 0A7, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N 3M5, Canada

  • UZ Leuven

    Leuven, 3000, Belgium

  • University College London

    London, WC1NAR, United Kingdom

  • University of Cincinnati Gardner Neuroscience Institute

    Cincinnati, Ohio, 45219, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Universitätsklinikum Ulm - Leimgrubenweg 12-14

    Ulm, 89075, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.